Cystic fibrosis (CF) is a life-limiting genetic disorder caused by mutations in the CFTR gene, leading to thick mucus that clogs the lungs, pancreas, and other organs. While pulmonary complications have traditionally dominated clinical focus, advances in care have extended life expectancy, bringing a new set of comorbidities to the forefront. One of the most significant is cystic fibrosis-related diabetes (CFRD), a distinct form of diabetes that shares features of both type 1 and type 2 diabetes. CFRD affects approximately 20% of adolescents with CF and up to 50% of adults over age 30. Unlike typical diabetes, CFRD is characterized by insulin deficiency due to progressive pancreatic destruction, combined with intermittent insulin resistance driven by infections and inflammation. Managing CFRD is uniquely difficult: patients must contend with unpredictable swings in blood glucose, high caloric and nutritional demands, frequent lung exacerbations, and the psychological burden of adding yet another chronic condition to their daily routine.

Biomedical engineering has emerged as a critical ally in this battle. By developing tools that automate monitoring, enhance insulin delivery, and integrate data across care domains, engineers are helping clinicians and patients achieve tighter glycemic control with less effort. This article explores the latest biomedical engineering innovations transforming CFRD management, the evidence behind them, and the future possibilities that promise to further improve outcomes.

CFRD occurs when the pancreas becomes damaged by scar tissue and mucus buildup, impairing its ability to produce insulin. Over time, the islet cells that secrete insulin are progressively destroyed. Insulin resistance can also occur during acute infections or while taking corticosteroids, further destabilizing glucose levels. The resulting hyperglycemia accelerates lung function decline, worsens nutritional status, and increases mortality.

Diagnosing CFRD requires an oral glucose tolerance test, but management is complicated by the fact that patients often have normal fasting glucose while experiencing postprandial hyperglycemia. Traditional self-monitoring of blood glucose (SMBG) with fingersticks provides limited snapshots, making it difficult to detect dangerous highs and lows. This is where biomedical engineering has made the first major impact.

Continuous Glucose Monitoring Systems: A New Standard of Care

Continuous glucose monitoring (CGM) has revolutionized diabetes management across all types, but for CFRD patients it is especially transformative. CGM systems use a small sensor inserted under the skin to measure interstitial glucose levels every few minutes, transmitting data wirelessly to a receiver or smartphone app. Real-time alerts warn of impending hypoglycemia or hyperglycemia, allowing immediate intervention.

Evidence for CGM in CFRD

Multiple studies have demonstrated that CGM improves glycemic control in CFRD. A 2020 randomized controlled trial published in Diabetes Care found that CGM use for 12 weeks significantly reduced time spent in hyperglycemia and improved hemoglobin A1c compared to standard SMBG alone. Another study from the University of Minnesota showed that CGM helped identify previously undetected nocturnal hypoglycemia in CF patients taking insulin, reducing dangerous events.

Modern CGM devices like the Dexcom G7 and Abbott FreeStyle Libre 3 are factory-calibrated, require no fingerstick calibration, and last up to 14 days. These advancements reduce the burden on patients who already manage complex medication regimens and frequent clinic visits. For caregivers and clinicians, CGM data can be accessed remotely, enabling proactive adjustments without requiring the patient to come in for an appointment.

Real-World Impact on Daily Life

The ability to see glucose trends in real time empowers patients to make informed decisions about meal timing, exercise, and insulin dosing. A 2022 qualitative study from the University of Michigan reported that CFRD patients using CGM felt more confident in managing their diabetes during social situations and physical activities. Parents of children with CFRD also expressed relief at being able to monitor glucose levels overnight, reducing fear of severe hypoglycemia while sleeping.

Smart Insulin Pens: Digitizing Insulin Delivery

While CGM addresses monitoring, smart insulin pens tackle the other half of the equation: insulin delivery. These connected devices automatically log the time, dose, and type of insulin injected, and sync with smartphone apps that track glucose trends. Some models, such as the InPen system, provide dose calculators based on current glucose, carbohydrate intake, and insulin on board, helping patients avoid stacking doses and reduce errors.

For CFRD patients who require multiple daily injections (MDI), smart pens offer a significant upgrade over traditional pens. The ability to share data with clinicians during telehealth visits has proven especially valuable for CF centers, where patients often live far from specialty clinics. A 2021 study in Pediatric Pulmonology reported that smart pen use in adolescents with CFRD improved adherence and reduced missed doses.

Integration with CGM Data

The true power of smart pens emerges when they are paired with CGM data. Combined systems display glucose levels, insulin doses, and activity patterns on a single dashboard. This integration helps identify patterns such as postprandial hyperglycemia or delayed hypoglycemia from exercise. Several apps now offer predictive dosing suggestions based on machine learning models trained on the patient’s own historical data.

Artificial Pancreas (Closed-Loop Systems)

The most advanced biomedical engineering solution for diabetes is the artificial pancreas, also known as a hybrid closed-loop system. These systems combine a CGM, an insulin pump, and a control algorithm that automatically adjusts insulin delivery based on real-time glucose readings. The user still needs to announce meals and calibrate occasionally, but the system handles basal rate adjustments and correction boluses.

Adaptations for CFRD

Initial closed-loop studies focused on type 1 diabetes, but researchers have now adapted algorithms for CFRD. The unique metabolic profile of CF patients—high carbohydrate intake, frequent infections, variable insulin sensitivity—requires specialized tuning. A pilot study from the University of Cambridge tested a closed-loop system in adults with CFRD and found that it maintained glucose in target range 15% more of the time compared to standard pump therapy, with no increase in hypoglycemia. A subsequent multicenter trial published in The Lancet Digital Health confirmed these results and showed improved quality-of-life scores among participants.

As of 2024, the Medtronic MiniMed 780G and Tandem t:slim X2 with Control-IQ are FDA-approved for type 1 diabetes but are used off-label for CFRD. Researchers are actively developing CFRD-specific algorithms that incorporate CF-specific variables such as predicted lung function decline and corticosteroid use. The hope is that within a few years, a dedicated CFRD closed-loop system will be available.

Challenges in Algorithm Design

One major challenge is the wide variability in insulin sensitivity that CFRD patients experience during pulmonary exacerbations. Standard closed-loop algorithms may overcorrect during periods of high insulin resistance, increasing hypoglycemia risk. New adaptive algorithms under development use real-time data from electronic health records, such as C-reactive protein levels and antibiotic courses, to adjust insulin delivery more precisely. The Cystic Fibrosis Trust is funding several projects to refine these algorithms.

Implantable Sensors and Long-Term Monitoring

Beyond external CGM, biomedical engineers are working on implantable glucose sensors that can last months or years without replacement. The Eversense system (Senseonics) is the first long-term implantable CGM, placed subcutaneously via a minor procedure and lasting up to 180 days. While currently indicated for type 1 and type 2 diabetes, its potential for CFRD patients is promising. An implantable sensor reduces the burden of frequent sensor changes, lowers the risk of skin irritation (common in CF patients who also use enzyme supplements and antibiotics), and provides continuous data even during hospitalizations for pulmonary exacerbations.

Researchers at MIT and Harvard are developing novel biosensors that measure glucose using fluorescence or near-infrared light, avoiding the electrochemistry that can degrade over time. These next-generation devices could be integrated with implantable insulin pumps to create fully internal closed-loop systems, eliminating external components altogether.

Addressing Skin Sensitivity

CF patients have notoriously sensitive skin due to chronic inflammation and frequent use of topical antibiotics. Up to 30% of CFRD patients report adhesive allergies or skin irritation from external CGM sensors, leading to early removal and gaps in data. Implantable sensors bypass this issue entirely. Alternatively, new hypoallergenic adhesives and smaller sensor profiles are being developed for external devices. The Cystic Fibrosis Foundation supports research into biocompatible materials for diabetes devices.

AI-Powered Decision Support

Biomedical engineering is not limited to hardware; software algorithms enhanced by artificial intelligence are becoming indispensable. Machine learning models can analyze historical glucose, insulin, nutrition, activity, and infection data to predict future glucose excursions and recommend optimal insulin doses. For CFRD patients whose disease trajectory is influenced by unpredictable factors like pulmonary exacerbations, these predictive tools are especially valuable.

A recent study from Stanford University trained a neural network on data from 50 CFRD patients and found that the model could predict next-hour glucose values with mean absolute error less than 15 mg/dL. Such algorithms are being integrated into CGM and smart pen apps to provide actionable insights, such as warning of an impending hypoglycemic event before it occurs or suggesting a preemptive insulin dose ahead of a high-carb meal.

Predicting Exacerbation Impact

Some advanced models go beyond glucose prediction. Researchers at the University of Pittsburgh have developed an AI tool that uses CGM data combined with electronic health records to predict when a CFRD patient is likely to experience a pulmonary exacerbation. Early warning allows clinicians to preemptively adjust insulin therapy and initiate antibiotics, potentially preventing hospitalizations.

Clinical Benefits and Patient Impact

The cumulative effect of these biomedical engineering advances is a measurable improvement in outcomes for CFRD patients. Tighter glycemic control slows lung function decline, reduces the frequency of hospitalizations, and improves nutritional status. A large retrospective study at the Cystic Fibrosis Foundation Patient Registry found that CFRD patients using CGM and pump therapy had significantly higher median FEV1 (forced expiratory volume in one second) values compared to those using injections and fingerstick monitoring.

Beyond clinical metrics, quality of life is enhanced. Patients report reduced anxiety about glucose management, fewer daily fingersticks, and greater confidence in managing their diabetes during social events, travel, and exercise. Caregivers also benefit from remote monitoring capabilities, which reduce worry when patients are away from home.

Reducing Hypoglycemia Risk

Hypoglycemia is a particular concern in CFRD because the combination of insulin therapy and high carbohydrate intake can lead to unpredictable drops. Closed-loop systems and CGM alerts have been shown to reduce severe hypoglycemia by up to 60% in type 1 diabetes, and early data suggest similar reductions in CFRD. This is crucial because hypoglycemia can exacerbate lung symptoms and lead to dangerous falls in blood sugar during sleep.

Improving Nutritional Outcomes

CFRD patients require high-calorie, high-fat diets to maintain body weight and lung function. Insulin therapy must be carefully balanced to prevent both hyperglycemia and weight loss from insulin deficiency. With CGM and smart insulin tools, patients are better able to match insulin doses to high-carb meals without causing hyperglycemia. A 2023 study in Journal of Cystic Fibrosis found that CFRD patients using advanced diabetes technologies had a lower incidence of unintended weight loss and better BMI maintenance over two years.

Challenges and Considerations

Despite the promise, integrating biomedical engineering into CFRD care faces several hurdles. Cost remains a major barrier: CGM systems, smart pens, and pumps are expensive, and insurance coverage for CFRD-specific indications is often limited. Many CF centers lack the specialized diabetes educators and endocrinologists needed to optimize device use in this patient population.

Another challenge is the added complexity of managing multiple devices. CFRD patients already deal with nebulizers, chest physiotherapy, enzyme supplements, and numerous oral medications. Adding a CGM, pump, and smartphone app can feel overwhelming. User-centered design that prioritizes ease of use and interoperability between devices is essential.

Biocompatibility issues also arise. CF patients often have sensitive skin due to chronic inflammation and repeated use of topical antibiotics, making adhesive allergies to CGM sensors a common problem. Researchers are developing hypoallergenic adhesives and minimizing sensor size to address this.

Finally, the lack of large-scale, long-term clinical trials specifically for CFRD limits the evidence base for device approval. Most studies to date have been small, single-center pilots. The Cystic Fibrosis Foundation and the National Institutes of Health are now funding multicenter trials to generate the data needed for formal FDA indications.

Future Directions

The next frontier in biomedical engineering for CFRD involves several converging trends. First, the development of fully implantable closed-loop systems using advanced materials and miniaturized sensors will eliminate external components, reducing infection risk and improving comfort. Second, biometric data integration will combine glucose readings with lung function, heart rate, physical activity, and sleep data from wearables to create holistic health dashboards for clinicians.

Third, gene therapy and CRISPR-based approaches are being explored to restore pancreatic function. While still in early stages, these techniques could theoretically prevent or reverse CFRD by repairing CFTR mutations in pancreatic islet cells. Biomedical engineers will play a role in designing delivery vehicles that target these cells effectively.

Finally, digital twins—AI-powered virtual models of individual patients—could enable personalized diabetes management simulations. By inputting a patient’s unique physiology, medication history, and lifestyle, a digital twin could predict the optimal insulin regimen and device settings, which clinicians could then apply in the real world. A proof-of-concept study for type 1 diabetes funded by the European Union’s Virtual Cloud project showed promising results, and adaptation for CFRD is underway.

Patient-Centered Design in Future Devices

Moving forward, input from CFRD patients and caregivers is being systematically incorporated into device design. Partnerships between device manufacturers and CF advocacy groups are ensuring that new products address real-world needs, such as simplified user interfaces, longer wear times, and integration with existing CF care apps. The goal is to make technology invisible—seamlessly woven into the patient's daily routine rather than adding to the burden.

Conclusion

Advances in biomedical engineering are fundamentally altering the landscape of diabetes management for patients with cystic fibrosis. From continuous glucose monitors and smart pens to closed-loop artificial pancreas systems and AI-driven decision support, these tools are delivering tighter glycemic control, fewer complications, and improved quality of life. While challenges related to cost, access, and device burden remain, ongoing innovation and dedicated research are steadily overcoming them.

As the cystic fibrosis community continues to live longer and healthier lives, the integration of sophisticated biomedical engineering solutions will be essential to managing the complex, dual diagnosis of CF and diabetes. By combining the ingenuity of engineers, the expertise of clinicians, and the resilience of patients, we are moving toward a future where CFRD no longer limits the potential of those who live with it.

For further reading, explore the Cystic Fibrosis Foundation’s CFRD resources page, the National Institute of Diabetes and Digestive and Kidney Diseases overview of CFRD, the latest research on PubMed, and the 2023 study on closed-loop systems in CFRD.